Cargando…

Fat-mass and obesity-associated gene polymorphisms and weight gain after risperidone treatment in first episode schizophrenia

BACKGROUND: Obesity induced by antipsychotics severely increases the risk of many diseases and significantly reduces quality of life. Genome Wide Association Studies has identified fat-mass and obesity-associated (FTO) gene associated with obesity. The relationship between the FTO gene and drug-indu...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Xueqin, Pang, Lijuan, Feng, Yufang, Fan, Xiaoduo, Li, Xue, Zhang, Wei, Gao, Jinsong, Zhang, Jianjiang, Nemani, Katlyn, Zhang, Hua, Lv, Luxian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282200/
https://www.ncbi.nlm.nih.gov/pubmed/25278160
http://dx.doi.org/10.1186/1744-9081-10-35
_version_ 1782351085420150784
author Song, Xueqin
Pang, Lijuan
Feng, Yufang
Fan, Xiaoduo
Li, Xue
Zhang, Wei
Gao, Jinsong
Zhang, Jianjiang
Nemani, Katlyn
Zhang, Hua
Lv, Luxian
author_facet Song, Xueqin
Pang, Lijuan
Feng, Yufang
Fan, Xiaoduo
Li, Xue
Zhang, Wei
Gao, Jinsong
Zhang, Jianjiang
Nemani, Katlyn
Zhang, Hua
Lv, Luxian
author_sort Song, Xueqin
collection PubMed
description BACKGROUND: Obesity induced by antipsychotics severely increases the risk of many diseases and significantly reduces quality of life. Genome Wide Association Studies has identified fat-mass and obesity-associated (FTO) gene associated with obesity. The relationship between the FTO gene and drug-induced obesity is unclear. METHOD: Two hundred and fifty drug naïve, Chinese Han patients with first-episode schizophrenia were enrolled in the study, and genotyped for four single nucleotide polymorphisms (SNPs rs9939609, rs8050136, rs1421085 and rs9930506) by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and direct sequencing. Body weight and body mass index (BMI) were measured at baseline and six months after risperidone treatment. RESULTS: At baseline, body weight and BMI of TT homozygotes were lower than those of A allele carriers in rs9939609; body weight of AA homozygotes was higher than those of G allele carriers in rs9930506 (p’s < 0.05). After 6 months of risperidone treatment, body weight and BMI of TT homozygotes were lower than those of A allele carriers in rs9939609 (p’s <0.01); body weight and BMI of CC homozygotes were lower than those of A allele carriers in rs8050136 (p’s < 0.05); body weight of AA homozygotes was higher than those of G allele carriers in rs9930506 (p’s < 0.05). After controlling for age, gender, age of illness onset, disease duration, weight at baseline and education, weight gain of TT homozygotes at 6 months remained to be lower than those of A allele carriers in rs9939609 (p < 0.01); weight gain of CC homozygotes at 6 months was lower than those of A allele carriers in rs8050136 (p = 0.01). Stepwise multiple regression analysis suggested that, among 4 SNPs, rs9939609 was the strongest predictor of weight gain after 6 months of risperidone treatment (p = 0.001). CONCLUSIONS: The FTO gene polymorphisms, especially rs9939609, seem to be related to weight gain after risperidone treatment in Chinese Han patients with first episode schizophrenia.
format Online
Article
Text
id pubmed-4282200
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42822002015-01-03 Fat-mass and obesity-associated gene polymorphisms and weight gain after risperidone treatment in first episode schizophrenia Song, Xueqin Pang, Lijuan Feng, Yufang Fan, Xiaoduo Li, Xue Zhang, Wei Gao, Jinsong Zhang, Jianjiang Nemani, Katlyn Zhang, Hua Lv, Luxian Behav Brain Funct Research BACKGROUND: Obesity induced by antipsychotics severely increases the risk of many diseases and significantly reduces quality of life. Genome Wide Association Studies has identified fat-mass and obesity-associated (FTO) gene associated with obesity. The relationship between the FTO gene and drug-induced obesity is unclear. METHOD: Two hundred and fifty drug naïve, Chinese Han patients with first-episode schizophrenia were enrolled in the study, and genotyped for four single nucleotide polymorphisms (SNPs rs9939609, rs8050136, rs1421085 and rs9930506) by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and direct sequencing. Body weight and body mass index (BMI) were measured at baseline and six months after risperidone treatment. RESULTS: At baseline, body weight and BMI of TT homozygotes were lower than those of A allele carriers in rs9939609; body weight of AA homozygotes was higher than those of G allele carriers in rs9930506 (p’s < 0.05). After 6 months of risperidone treatment, body weight and BMI of TT homozygotes were lower than those of A allele carriers in rs9939609 (p’s <0.01); body weight and BMI of CC homozygotes were lower than those of A allele carriers in rs8050136 (p’s < 0.05); body weight of AA homozygotes was higher than those of G allele carriers in rs9930506 (p’s < 0.05). After controlling for age, gender, age of illness onset, disease duration, weight at baseline and education, weight gain of TT homozygotes at 6 months remained to be lower than those of A allele carriers in rs9939609 (p < 0.01); weight gain of CC homozygotes at 6 months was lower than those of A allele carriers in rs8050136 (p = 0.01). Stepwise multiple regression analysis suggested that, among 4 SNPs, rs9939609 was the strongest predictor of weight gain after 6 months of risperidone treatment (p = 0.001). CONCLUSIONS: The FTO gene polymorphisms, especially rs9939609, seem to be related to weight gain after risperidone treatment in Chinese Han patients with first episode schizophrenia. BioMed Central 2014-10-02 /pmc/articles/PMC4282200/ /pubmed/25278160 http://dx.doi.org/10.1186/1744-9081-10-35 Text en © Song et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Song, Xueqin
Pang, Lijuan
Feng, Yufang
Fan, Xiaoduo
Li, Xue
Zhang, Wei
Gao, Jinsong
Zhang, Jianjiang
Nemani, Katlyn
Zhang, Hua
Lv, Luxian
Fat-mass and obesity-associated gene polymorphisms and weight gain after risperidone treatment in first episode schizophrenia
title Fat-mass and obesity-associated gene polymorphisms and weight gain after risperidone treatment in first episode schizophrenia
title_full Fat-mass and obesity-associated gene polymorphisms and weight gain after risperidone treatment in first episode schizophrenia
title_fullStr Fat-mass and obesity-associated gene polymorphisms and weight gain after risperidone treatment in first episode schizophrenia
title_full_unstemmed Fat-mass and obesity-associated gene polymorphisms and weight gain after risperidone treatment in first episode schizophrenia
title_short Fat-mass and obesity-associated gene polymorphisms and weight gain after risperidone treatment in first episode schizophrenia
title_sort fat-mass and obesity-associated gene polymorphisms and weight gain after risperidone treatment in first episode schizophrenia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282200/
https://www.ncbi.nlm.nih.gov/pubmed/25278160
http://dx.doi.org/10.1186/1744-9081-10-35
work_keys_str_mv AT songxueqin fatmassandobesityassociatedgenepolymorphismsandweightgainafterrisperidonetreatmentinfirstepisodeschizophrenia
AT panglijuan fatmassandobesityassociatedgenepolymorphismsandweightgainafterrisperidonetreatmentinfirstepisodeschizophrenia
AT fengyufang fatmassandobesityassociatedgenepolymorphismsandweightgainafterrisperidonetreatmentinfirstepisodeschizophrenia
AT fanxiaoduo fatmassandobesityassociatedgenepolymorphismsandweightgainafterrisperidonetreatmentinfirstepisodeschizophrenia
AT lixue fatmassandobesityassociatedgenepolymorphismsandweightgainafterrisperidonetreatmentinfirstepisodeschizophrenia
AT zhangwei fatmassandobesityassociatedgenepolymorphismsandweightgainafterrisperidonetreatmentinfirstepisodeschizophrenia
AT gaojinsong fatmassandobesityassociatedgenepolymorphismsandweightgainafterrisperidonetreatmentinfirstepisodeschizophrenia
AT zhangjianjiang fatmassandobesityassociatedgenepolymorphismsandweightgainafterrisperidonetreatmentinfirstepisodeschizophrenia
AT nemanikatlyn fatmassandobesityassociatedgenepolymorphismsandweightgainafterrisperidonetreatmentinfirstepisodeschizophrenia
AT zhanghua fatmassandobesityassociatedgenepolymorphismsandweightgainafterrisperidonetreatmentinfirstepisodeschizophrenia
AT lvluxian fatmassandobesityassociatedgenepolymorphismsandweightgainafterrisperidonetreatmentinfirstepisodeschizophrenia